AAA817 (225Ac-PSMA-617) phase 2/3 trial

[Maxone73]

The PSMAcTION trial is a Phase II/III open-label, multicenter study evaluating the investigational drug AAA817 (225Ac-PSMA-617) for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Patients who previously received androgen receptor pathway inhibitors (ARPI), taxane-based chemotherapy, and progressed after [177Lu]Lu-PSMA therapy are eligible.

The Phase II portion gathers data to support dosing, while the Phase III component compares AAA817’s efficacy and safety against standard-of-care treatments.

Participants will be randomly assigned to either the AAA817 arm or investigator-chosen standard treatments.

This study aims to offer a new therapeutic option for advanced mCRPC, providing hope for patients with limited treatment alternatives.

prostatewarriors.com/2025/0...

[PC-22]

Thanks for this info. I just looked it up on clinicaltrials.gov. Unfortunately, the only location I see is in Singapore.

[Maxone73 in reply to PC-22]

which state or country would be closer to you?

[Maxone73 in reply to PC-22]

You could maybe look into this: healthunlocked.com/fight-pr...